Fu Y, Zhu R, Bai T, et al. - This multicenter, retrospective study was designed to investigate clinical features as well as prognosis of coronavirus disease 2019 (COVID‐19) patients exhibiting elevated liver biochemistries. Data on laboratory‐verified COVID‐19 cases were obtained from three hospitals in Wuhan, China, including patients who died or were discharged between February 1, 2020, and February 20, 2020. Enrolled patients were 482 in total, with abnormal liver biochemistries on admission in 142 (29.5%). In COVID‐19 patients, independent factors related to elevated liver biochemistries were: chest distress or pain, dyspnea, elevated C‐reactive protein level, increased white blood count, and elevated Hb level, as revealed in the multivariable regression analysis. Overall, findings revealed that COVID‐19 patients commonly had elevated liver biochemistries. Increased liver biochemistries on admission were more likely to be seen in patients with hypoxia or severe inflammation. Severe complications and death were more likely to be encountered by patients with abnormal aspartate aminotransferase or total bilirubin on admission.